VERTEX PHARMACEUTICALS INC / MA Insider Trading Activity
Every SEC Form 4 insider transaction reported for VERTEX PHARMACEUTICALS INC / MA (VRTX), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are VRTX insiders buying or selling?
In the last 12 months, VERTEX PHARMACEUTICALS INC / MA insiders reported 0 open-market purchases ($0) and 52 sales ($158.1M) — net selling of $158.1M. Since January 2018, Trabud has recorded 575 Form 4 filings for VRTX: 5 buys ($14.0M) and 570 sells ($1.1B).
Source: SEC EDGAR Form 4
What stands out
- No VERTEX PHARMACEUTICALS INC / MA insider made an open-market purchase in the last 12 months; the 52 reported open-market sales totaled $158.1M.
Key Statistics (January 2018 – Jul 7, 2026)
Total Form 4 filings
575
SEC EDGAR
Insider filers
27
Insider buys (5)
$14.0M
Insider sells (570)
$1.1B
Insider sentiment
Net sellingNet insider flow of $1.0B in net selling since January 2018, and $158.1M in net selling over the last 12 months.
Recent VRTX insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jul 7, 2026 | Ourania Tatsis | EVP, Chief Reg. & Quality Off. | Sale | 1.5K | $524.99 | $787.5K | SEC ↗ |
| Jul 7, 2026 | Duncan Mckechnie | EVP, Chief Commercial Officer | Sale | 1.5K | $519.00 | $799.8K | SEC ↗ |
| Jul 6, 2026 | Joy Liu | EVP and Chief Legal Officer | Sale | 828 | $502.71 | $416.2K | SEC ↗ |
| Jun 30, 2026 | Carmen Bozic | EVP and CMO | Sale | 596 | $482.50 | $287.6K | SEC ↗ |
| Jun 23, 2026 | Carmen Bozic | EVP and CMO | Sale | 1.0K | $462.17 | $471.4K | SEC ↗ |
| Jun 17, 2026 | Carmen Bozic | EVP and CMO | Sale | 4.1K | $450.00 | $1.8M | SEC ↗ |
| Jun 9, 2026 | Carmen Bozic | EVP and CMO | Sale | 1.7K | $450.00 | $785.3K | SEC ↗ |
| Jun 3, 2026 | Joy Liu | EVP and Chief Legal Officer | Sale | 828 | $439.91 | $364.2K | SEC ↗ |
| Jun 2, 2026 | Carmen Bozic | EVP and CMO | Sale | 2.0K | $450.00 | $888.3K | SEC ↗ |
| May 19, 2026 | Mark E. Bunnage | EVP, Chief Scientific Officer | Sale | 33 | $453.45 | $15.0K | SEC ↗ |
| May 19, 2026 | Carmen Bozic | EVP and CMO | Sale | 1.4K | $453.45 | $614.0K | SEC ↗ |
| May 14, 2026 | Carmen Bozic | EVP and CMO | Sale | 7.0K | $450.00 | $3.1M | SEC ↗ |
| May 5, 2026 | Joy Liu | EVP and Chief Legal Officer | Sale | 1.1K | $425.02 | $469.2K | SEC ↗ |
| May 5, 2026 | Sangeeta N. Bhatia | Director | Sale | 318 | $423.73 | $134.7K | SEC ↗ |
| Apr 3, 2026 | Joy Liu | EVP and Chief Legal Officer | Sale | 978 | $449.17 | $439.3K | SEC ↗ |
| Mar 31, 2026 | Carmen Bozic | EVP and CMO | Sale | 2.3K | $450.95 | $1.1M | SEC ↗ |
| Mar 17, 2026 | Carmen Bozic | EVP and CMO | Sale | 2.3K | $481.79 | $1.1M | SEC ↗ |
| Mar 13, 2026 | Duncan Mckechnie | EVP, Chief Commercial Officer | Sale | 2.6K | $498.42 | $1.3M | SEC ↗ |
| Mar 6, 2026 | Duncan Mckechnie | EVP, Chief Commercial Officer | Sale | 2.4K | $475.30 | $1.2M | SEC ↗ |
| Mar 4, 2026 | Joy Liu | EVP and Chief Legal Officer | Sale | 892 | $495.96 | $442.4K | SEC ↗ |
| Mar 3, 2026 | Reshma Kewalramani | CEO & President | Sale | 40.0K | $493.47 | $19.7M | SEC ↗ |
| Mar 3, 2026 | Carmen Bozic | EVP and CMO | Sale | 2.3K | $480.31 | $1.1M | SEC ↗ |
| Mar 2, 2026 | Kristen Ambrose | SVP & Chief Accounting Officer | Sale | 357 | $483.36 | $172.6K | SEC ↗ |
| Feb 26, 2026 | Ourania Tatsis | EVP, Chief Reg. & Quality Off. | Sale | 260 | $486.35 | $126.5K | SEC ↗ |
| Feb 26, 2026 | Amit Sachdev | EVP Chief Patient & Ext Af Off | Sale | 1.8K | $486.35 | $897.8K | SEC ↗ |
Showing the 25 most recent of 575 Form 4 filings for VERTEX PHARMACEUTICALS INC / MA.
Most active VRTX insiders
- David Altshuler71 filings
- Stuart A Arbuckle65 filings
- Michael Parini55 filings
- Amit Sachdev50 filings
- Paul M Silva41 filings
Ask anything about VRTX insider activity
Use Trabud's AI agent to query VERTEX PHARMACEUTICALS INC / MA's Form 4 history in plain English — "Show me VRTX CEO purchases this year" or compare it against any other ticker.
Open the AI agentVRTX insider trading FAQ
Are VERTEX PHARMACEUTICALS INC / MA insiders buying or selling?
In the last 12 months, VERTEX PHARMACEUTICALS INC / MA insiders reported 0 open-market purchases ($0) and 52 sales ($158.1M) — net selling of $158.1M. Since January 2018, Trabud has recorded 575 Form 4 filings for VRTX: 5 buys ($14.0M) and 570 sells ($1.1B). Over the full record that is net selling of $1.0B.
How many insiders trade VRTX stock?
27 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for VERTEX PHARMACEUTICALS INC / MA. The most recent filing was accepted on Jul 7, 2026.
Where does Trabud get VRTX insider trading data?
All VRTX insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.